Propel Bio Management, LLC / TCE2
Propel Bio Management, LLC’s Celldex Therapeutics Inc New Position
Does Propel Bio Management, LLC own Celldex Therapeutics Inc New (TCE2)? Yes — 131.4K shares worth $4M (+2.61% of its 13F portfolio) as of Q1 2026, down from 154.3K shares the prior filed quarter.
Position Value
$4M
Q1 2026
Shares
131.4K
% of Portfolio
+2.61%
Quarters Held
3
currently held
Position History TCE2
Reported value by quarter
Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Propel Bio Management, LLC’s full portfolio or all institutional holders of TCE2.